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Abstract  
Objective: Healthcare professionals (HCPs) are required to assess and train patients in the correct 
use of inhalers but are often unable to demonstrate correct technique themselves. We sought to 
assess the level of training required for HCPs to master and maintain device mastery when using 
two different dry powder inhalers (DPIs). Methods: We conducted a randomised, un-blinded, 
cross-over study in undergraduate HCPs who undertook a stepwise training (from step 1, intuitive 
use, to step 6, expert tuition) in the use of Turbuhaler® (an established device) and Spiromax® (a 
newer, reportedly easier to use device). Device mastery (absence of errors) was evaluated by 
expert assessors at each step. Maintenance of device mastery was assessed 4 ± 1 week (visit 2) 
and 8 ± 2 weeks (visit 3) after initial training (visit 1). Results: Of 516 eligible participants, 113 
(22%) demonstrated device mastery prior to training on Spiromax® compared with 20 (4%) on 
Turbuhaler® (p<0.001). The median number of steps required to achieve mastery was 2 (patient 
information leaflet; interquartile range [IQR] 2–4) for Spiromax® and 3 (instructional video; IQR 
2–4) for Turbuhaler® (p<0.001). A higher number of participants maintained mastery with 
Spiromax® compared with Turbuhaler® both at visits 2 and 3 (64% vs 41% and 79% vs 65%, 
respectively; p<0.001). Conclusions: There are significant differences in the nature and extent of 
training required to achieve and maintain mastery for different DPIs. The implications of this on 
clinical practice, device education delivery and patient outcomes require further evaluation. 
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Introduction  
Inhalers are the most commonly used devices to deliver pharmacological treatments for asthma 
and chronic obstructive pulmonary disease (COPD). Because correct use of inhalers is central to 
effective therapy, poor inhaler technique not only compromises disease control [1] but also 
consequently increases the economic burden of asthma management [2]. Unfortunately, incorrect 
inhaler use remains common in clinical practice [3] and this aspect has not improved over the past 
40 years [4]. This has prompted international organisations of clinicians and health care providers 
to recognise the importance of patient education by healthcare professionals (HCPs) [5]. The 
Global Initiative for Asthma (GINA) Guidelines recommend training patients in the use of 
inhalers as a fundamental and essential component of good clinical practice and consequently 
advise that HCPs assess and train patients in inhaler use at every clinical encounter [6]. Research 
has shown that face-to-face training substantially improves patients’ ability to use their inhalers 
correctly [7, 8]. However, as shown by previous studies, many HCPs lack the basic knowledge 
and technical skill to teach different inhaler techniques [9-11] and they seldom receive formal 
training in the use of inhalers [12]. Finding solutions to this major problem is of utmost 
importance to improve the control of asthma and COPD in the population [13]. While it is 
important to explore the way in which HCPs are currently trained in the use of inhalers, at present 
it is unfortunately unrealistic to believe that (as is the requirement for patients) each HCP will 
have the opportunity to receive hands-on individualised training. This puts the onus on each 
individual HCP and this is where more intuitive devices might be of help. Many of the newer 
devices are reported to be easier to use [14-16]; however, it is still unknown what this actually 
means for HCPs. While HCPs have been shown to retain device mastery more efficiently when 
they have the opportunity to educate their patients [17], it appears important to assess the impact 
of newer and allegedly more intuitive devices on their ability to retain mastery over time.   
The aim of this study was to assess the nature and extent of training required for HCPs to master 
and maintain correct inhaler technique when using two different dry powder inhalers (DPIs), in 
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particular comparing the role of newer, reportedly simpler to use DPIs with that of more 
established DPIs. To address these research questions, we conducted a randomised, un-blinded, 
cross-over study in pharmacist, physician and nursing undergraduates and compared Spiromax® 
(an example of a newer device) with Turbuhaler® (an example of an established device). These 
two particular inhalers were chosen as relevant comparators on the basis that they are both DPIs 
licensed in Europe for the delivery of budesonide/formoterol combination therapy for asthma but 
differ in terms of design and dose preparation steps.  
 
Methods  
Study design and subjects 
This was a multi-centre, randomised, un-blinded, cross-over study conducted between July 2014 
and June 2015 (ClinicalTrials.gov Identifier: NCT02570425). The study was approved by the 
Human Research Ethics Committees of the University of Sydney (Project No.: 2014/344) and was 
performed in accordance with the National Health and Medical Research Council’s (NHMRC) 
National Statement on Ethical Conduct in Human Research (2007) Australia and with the 
principles of the Declaration of Helsinki. The sampling frame was all undergraduate Bachelor of 
Pharmacy students (Year 1) from the University of Sydney (Australia), Bachelor of Nursing 
Students (Year 1) from the University of Sydney, Doctor of Medicine Students (Year 2) from the 
University of Sydney, and Doctor of Medicine Students (Year 2) from UNSW Australia. 
Participants were recruited via relevant e-learning websites, promotion of the study at lectures, 
and provision of participant information at tutorials. Students who chose to participate in the 
study were screened for eligibility and enrolled if they met the following inclusion criteria: 
provided written and informed consent; were willing to comply with study restrictions and attend 
study visits as specified; were enrolled in one of the specified University departments; had not 
used or received training in the use of either Turbuhaler® or Spiromax® in the last 6 months. 
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Potential participants were excluded from the study if they had a current diagnosis of asthma, a 
past diagnosis of asthma, or both.  
Study devices 
Turbuhaler® and Spiromax® empty devices were used for this study. Turbuhaler® (AstraZeneca, 
Sweden) is a multidose DPI consisting of a protective cover, mouthpiece, drug reservoir with dose 
indicator, and a rotating grip at the base; dose preparation requires holding the device in the 
upright position and a full rotation of the grip [18]. Spiromax® (Teva Pharmaceutical Industries, 
Petach Tikva, Israel) is a multidose DPI with design similar to a pressurised metered-dose inhaler 
(pMDI) but uses an X-ACT® technology for drug delivery [19]. Dose preparation consists in 
opening the cap until one click is heard while holding the device with the mouthpiece cover at the 
bottom [20]. For both devices, we compiled a checklist of errors potentially impairing drug 
delivery to the lungs. These errors were identified a priori based on the manufacturer’s 
instructions included in the patient information leaflet [18, 20] and on expert steering committee 
advice [21]. The checklists include errors associated with dose preparation, position of the inhaler, 
inhalation manoeuvre, and general knowledge of device use (Table S1). 
Study procedures 
The study consisted of three visits over a period of 8 ± 2 weeks. At each visit, and before starting 
any procedure, baseline data (demographic characteristics and history of inhaler device use prior 
to study) were collected.  
At visit 1, participants were randomly assigned to either Turbuhaler® training followed by 
Spiromax® training or Spiromax® training followed by Turbuhaler® training (cross-over design) 
(Figure 1). The training procedure was designed to represent best clinical practice, current 
available mode of education, and to address the educational needs of HCPs. It consisted in a step-
wise process in which participants were assessed on their ability to use the device through 6 
consecutive steps: (1) intuitive use; (2) use of patient information leaflet; (3) use of instructional 
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video; (4) expert tuition; (5-6) repeats of expert tuition (see Table S2 for details of instructions 
provided at each step). At each step, participants were monitored by expert assessors specifically 
trained to provide education and feedback to device users; errors in device use were recorded 
according to the device checklist (Table S1). Participants progressed from one step to the next 
until they achieved device mastery (defined as the ability to demonstrate inhaler use without 
assessor-observed errors) or until completion of all 6 training steps (Figure 2). They then 
proceeded to complete the same training and assessment process with the second empty device. 
At the end of the visit, participants were asked to rate their satisfaction for each device by 
completing Part II question 15 of the Patient Satisfaction and Preference Questionnaire 
(PASAPQ). PASAPQ is a multi-item measure of satisfaction and preference for respiratory 
inhalation devices [22].  
Visits 2 and 3 commenced 4 weeks (± 1 week) and 8 weeks (± 2 weeks) after visit 1, respectively. 
Participants were once again randomly assigned to receive step-by-step device training on 
Turbuhaler® followed by Spiromax® or Spiromax® followed by Turbuhaler® to determine whether 
device mastery had been maintained over the 4- and 8-week time period. If they did not maintain 
device mastery at step 1, participants were trained as in visit 1 until device mastery was re-
established. Device preference was again assessed using the PASAPQ Part II question 15 at the 
end of the visit. 
Study definitions and outcomes 
Device mastery (yes/no) was defined as the ability to demonstrate inhaler use without assessor-
observed errors. Maintenance of device mastery, assessed at visits 2 and 3, was defined as the 
ability to demonstrate correct inhaler use without the need to undertake any further training (i.e., 
no errors at step 1). 
The primary outcome was maintenance of device mastery at visit 2. Secondary outcomes included 
maintenance of device mastery at visit 3 and, for each visit, the following: achievement of device 
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mastery by steps 1, 2, and 3; number of steps required to achieve mastery; number and type of 
errors made; and participants’ preference for the inhaler.  
Statistical analyses 
Data were analysed using Statistical Analysis Software version 9.3 (SAS Institute Inc). The study 
was powered on the primary outcome, maintenance of device mastery at visit 2. Based on results 
from a similar study [7], a sample size of 137 pairs (137 subjects evaluated on both inhalers) was 
required to have 90% power to detect a difference in proportion of subjects maintaining device 
mastery of 0.177 (= 0.789-0.612), when the proportion of discordant pairs is expected to be 0.431 
and the method of analysis is the McNemar's test of equality of paired proportions (with a 0.05 
two-sided significance level). Taking into account a drop-out rate of 10% between visits, a 
minimum of 144 pairs was therefore required for visit 1.  
The McNemar’s test was used to compare the proportion of subjects achieving mastery of inhaler 
technique between the two devices. Conditional logistic regression was used to quantify the 
difference between the two devices by calculating the odds ratio (OR) for achieving mastery for 
Spiromax® (with Turbuhaler® as the reference device) with a 95% confidence interval (CI). When 
CI does not contain 1.00, results are statistically significant at the 5% level. The Chi-squared and 
Wilcoxon signed rank tests were used to compare the proportion of participants achieving device 
mastery stratified by the order of randomisation and the mean/median number of levels required 
to achieve device mastery between the two devices, respectively. For all analyses where P-value 
is provided, statistical significance was set at 0.05.  
Summary statistics collected at each visit included: number of levels required to achieve device 
mastery, number and type of assessor-observed errors (total of errors made at all steps) and device 
preference. Continuous variables (including age and number of levels taken to achieve device 
mastery) were summarised by reporting their mean/median along with their standard 
deviations/interquartile range (IQR). Categorical variables were reported as frequencies and 
percentage proportions. In particular, device mastery (yes/no) was expressed as cumulative 
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number and percentage of participants achieving device mastery by each training step, unless 
otherwise stated. Participant demographic and baseline characteristics were summarised using 
descriptive statistics. 
Results 
Participant disposition and characteristics  
A total of 542 participants were enrolled in the study; of these, 516 (39% male, mean age 23 ± 5 
years) met the eligibility criteria and were randomised into visit 1. Four hundred ninety-eight and 
460 participants were eligible for visits 2 and 3, respectively. Figure S1 and Table S3 show the 
disposition and the demographic characteristics of participants at each visit of the study, 
respectively. 
Achieving device mastery 
At visit 1, the odds of making a device error prior to training was significantly lower for 
Spiromax® compared with Turbuhaler® (OR 0.16 [95% CI 0.10–0.27]). A total of 113 (22%) 
participants demonstrated device mastery at step 1 on Spiromax® compared with 20 (4%) 
participants achieving mastery on Turbuhaler® (p<0.001; McNemar’s test of paired data) (Table 
1). Likewise, a significantly higher number of participants achieved mastery in the use of 
Spiromax® by steps 2 and 3 (p<0.001). This effect was independent of device randomisation order 
(steps 1 and 2, p<0.001 for both randomisation orders; step 3, p<0.05 for both randomisation 
orders; Chi-squared test) (Table 1). By step 4 (expert tuition), about 90% of participants achieved 
device mastery, with no statistical difference between the devices (data not shown).  
At visit 1, the median number of steps required to achieve device mastery was 2 (patient 
information leaflet; [IQR] 2–4) for Spiromax® and 3 (instructional video; IQR 2–4) for 
Turbuhaler® (p<0.001; Wilcoxon Signed-Rank test).  
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Maintaining device mastery  
Visit 2 
At visit 2, a total of 317 (64%) participants had maintained device mastery with Spiromax® 
compared with 202 (41%) participants who had maintained device mastery with Turbuhaler® 
(p<0.001; McNemar’s test of paired data) (Table 2). This effect was independent of device 
randomisation order (Table 2). The odds of making a device error was significantly lower for 
Spiromax® compared with Turbuhaler® (OR 0.37 [95% CI 0.28–0.48]).  
By steps 2 and 3, a significantly higher number of participants achieved mastery in the use of 
Spiromax® as compared with Turbuhaler® (p<0.001 and p=0.022 for steps 2 and 3, respectively; 
McNemar’s test of paired data). This effect was associated with device randomisation order: at 
both steps, significantly more participants using Spiromax® as first device achieved device 
mastery compared with participants using Turbuhaler® as first device (p<0.001 and p=0.007 for 
steps 2 and 3, respectively; Chi-squared test); however, there was no significant difference in 
device mastery when Spiromax® and Turbuhaler® were used as second device (step 2, p=0.347; 
step 3, p=1.00) (Table 2). The median number of steps required to achieve device mastery was 1 
(intuitive use; IQR 1–2) for Spiromax® and 2 (patient information leaflet; IQR 1–2) for 
Turbuhaler® (p<0.001; Wilcoxon Signed-Rank test).  
Visit 3 
At visit 3, a total of 362 (79%) participants maintained device mastery on Spiromax® prior to 
training compared with 299 (65%) participants who maintained device mastery on Turbuhaler® 
(p<0.001; McNemar’s test of paired data); this effect was independent of device randomisation 
order (Table 3). The odds of making a device error was significantly lower for Spiromax® 
compared with Turbuhaler® (OR 0.50 [95% CI 0.37–0.68]).  
Already by step 2, over 90% of participants demonstrated device mastery on both inhalers with no 
significant difference between the two devices (Table 3). Likewise, there was no significant 
difference in the median number of steps required to achieve device mastery between the two 
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devices (median number of steps 1, IQR 1–1 for Spiromax® and 1–2 for Turbuhaler®; p=0.111; 
Wilcoxon Signed-Rank test).  
Figure 3 summaries the proportion of participants achieving and maintaining device mastery over 
the study period.  
Number and types of errors made  
At each visit, a significantly higher number of errors were made on Turbuhaler® than on 
Spiromax® (total number of errors made at all steps: 2540 vs 1447 at visit 1; 780 vs 367 at visit 2; 
296 vs 175 at visit 3). The most common device errors made at each visit are reported in Table 4. 
The error ‘not twisting the base as far as possible’ related to dose preparation was the most 
common for Turbuhaler® at visits 1 and 2 (made by 389 [75%] and 155 [31%] participants, 
respectively) and the second most common at visit 3 (Table 4). The error ‘inhalation not as fast as 
possible from the start’ in inhalation manoeuvre was the most common for Spiromax® at all visits 
(337 [65%], 96 [19%] and 50 [11%] at visits 1, 2, and 3, respectively). This error was one of the 
most frequent also for Turbuhaler® (reported for 323 [63%] and 107 [22%] participants at visits 1 
and 2, respectively). Finally, errors related to inhaler position were common for both inhalers 
(Table 4).  
Participants’ preference for the inhaler  
At visit 1, 487 (94%) participants completed question 15 of the PASAPQ PART II. Of these, 74% 
rated Spiromax® as their preferred device compared with 16% who rated Turbuhaler® as their 
preferred device (10% of participants reported no preference). Also at visits 2 and 3, Spiromax® 
was the preferred device over Turbuhaler® (75% vs 16% at visit 2 [9% no preference], 79% vs 
14% at visit 3 [7% no preference]).  
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Discussion  
We conducted a randomised, un-blinded, cross-over study assessing the nature and extent of 
training required for undergraduate HCPs to master inhaler technique and maintain it over time 
when using different DPI devices. In particular, we compared the role of newer, reportedly easier 
to use devices (Spiromax® in this study) with that of more established devices (Turbuhaler® in 
this study). We found that undergraduate HCPs demonstrated fewer device errors and required 
fewer training steps to master inhaler technique when using Spiromax® compared with 
Turbuhaler®. Once established, a higher number of HCPs maintained mastery with Spiromax® 
than with Turbuhaler® over a period of 2 months. Given that not all HCPs are regular inhaler users, 
and that there has been an upsurge of new inhalers on the market over the last few years, this 
study was crucial to understanding how and when undergraduate HCPs need to have their inhaler 
technique skills developed and refreshed. We believe that this knowledge will help to develop 
strategies to better support HCPs in the management of patients with respiratory diseases. 
 
Sandler et al [14] have recently shown that Spiromax® is easier to learn to use compared with 
Turbuhaler® and Easyhaler® when tested in healthy volunteers naïve to all three devices. Our data 
on device mastery shows that this is the case also for undergraduate HCPs. This may be due to 
Spiromax® having fewer preparation steps for dose delivery. In our study, a large number of 
participants failed to correctly demonstrate dose preparation steps for Turbuhaler® (twisting the 
base as far as possible and holding the device upright); Spiromax® does not require all of these 
steps for preparing the dose. In terms of the level of training required to achieve mastery, we 
made the following observations: 1) at visit 1, 60% of participants using Spiromax® achieved 
mastery with written information, whereas for Turbuhaler® a video instruction was required for a 
comparable proportion of participants to achieve mastery; 2) although many participants were 
able to achieve device mastery after the first three steps of training, some participants did require 
additional training through individualised feedback to achieve mastery. These findings have 
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practical implications as they suggest that for Spiromax® the written instructions provided in 
package inserts are sufficient to train a substantial percentage of individuals whereas, for 
Turbuhaler®, many individuals will need video instructions or demonstration by trained HCPs to 
learn how to use the device correctly. Further, while video instructions are often provided on both 
manufacturers’ and patients’ websites, providing expert tuition would require allocating specific 
resources for the training of HCPs. From this perspective, it may be important to determine the 
cost-effectiveness of delivering personalised training to HCPs for different inhalers. 
Inhalers that are more intuitive/easier to use may paradoxically increase the risk of errors in 
subsequent usage, i.e. subjects who demonstrate correct technique or achieve device mastery with 
little training in the first place may do so by chance and therefore may not perform as well at 
subsequent visits; by contrast subjects who need more inputs/training may achieve a better 
understanding of the device and thus perform better in the future. However, when reassessing 
device mastery 1 month and 2 months after initial training, we found that a higher number of 
participants maintained correct technique on Spiromax® than on Turbuhaler®. This suggests that, 
once the technique is established for easier to use inhalers, HCPs may be able to maintain mastery 
over time with no or little additional training. Nonetheless, it should be noted that 1 and 2 months 
after the initial training, a high percentage of participants demonstrated correct technique with 
both devices after refreshing their skills via written instructions. This indicates that, if proper 
training is provided initially, educating HCPs to refresh their skills periodically via minimal 
instructions may have a big impact on their ability to use inhalers correctly, and subsequently 
train patients appropriately, in the long term.  
The superior ease of use may explain why the majority of participants rated Spiromax® as their 
preferred device compared with Turbuhaler®. Similar results were reported by studies that 
compared device preference between Spiromax® and Turbuhaler® among healthy volunteers [14] 
and patients with asthma [23]. This may have implications for clinical practice, as patients’ 
  14 
preference may affect adherence and thus is an important factor that HCPs are encouraged to 
consider when prescribing/switching inhalers [24].  
When taking randomisation order into account, we observed a learning effect. During initial 
training (visit 1), for both Spiromax® and Turbuhaler® the percentage of participants 
demonstrating device mastery when the inhaler was used as the second device was higher than the 
percentage of participants demonstrating mastery when the inhaler was used as the first device. 
This was true for steps 1, 2 and 3 though at step 1 the percentage increased by three and six times 
for Spiromax® and Turbuhaler®, respectively. This suggests that there may be ‘carry-over’ effects 
in terms of generic skills of inhaler use. The presence of any ‘carry-over’ effect needs to be 
explored in future research and the implications for practice considered. 
When considering the errors, participants made fewer errors when using Spiromax® than when 
using Turbuhaler®. Throughout the study the errors remained generally consistent for both devices 
though, as expected, less frequent. The most common error for Turbuhaler® was ‘not twisting the 
base as far as possible until it clicks and not turning it back to the original position’, which relates 
to dose preparation and thus is crucial to ensure correct drug delivery. ‘Inhalation not as fast as 
possible from the start’ was the third most common error for Turbuhaler® and the most common 
error for Spiromax®, and was displayed by a similar proportion of participants for the two devices. 
Failure to inhale as fast as possible is a common error for DPIs [21, 24, 25], thus the similar 
number of users demonstrating this error with either device is as expected. Because correct 
inhalation technique is critical to appropriate medication intake, HCPs should be particularly 
mindful of this error when training patients in the use of any DPI. It should be noted that although 
‘holding the inhaler in the upright position (±90°) during dose preparation’ was included in the 
manufacturer’s instructions for Spiromax® at the time in which this research was performed, a 
recent study [19] has shown that dose consistency is maintained with Spiromax® regardless of 
device orientation (±45° tested in addition to ±90°). In light of this, this position error may not 
represent a critical error for Spiromax®.  
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Basheti et al [26] have recently addressed the issue of heterogeneity of error checklists in the field 
and provided recommendations about standardised checklists for two DPIs, Diskus® and 
Turbuhaler®. The list used for Turbuhaler® in the present study followed their recommendations 
and although such recommendations are not currently available for the more recent device 
Spiromax®, our checklists were generated by expert opinion and included errors that have been 
used in previous studies [14]. The errors considered here are those commonly seen in clinical 
practice, which have potential implications on device effectiveness; however, they are not a 
validated measure. Although some studies have investigated the impact of inhaler misuse or the 
number of inhaler errors on asthma control [3, 25] and management [1], knowledge of the 
relationship between individual inhaler errors and asthma outcomes is still limited. This 
knowledge would be crucial to better identify critical errors and develop educational interventions 
for HCPs and patients tailored to address such errors specifically.  
There are some limitations in the study design. This was primarily an ‘evaluation-of-concept’ 
study that analysed a cohort of undergraduate HCPs with a mean age of 23. This is a very specific 
cohort and thus our findings may not be generalisable to patients with chronic airways disease or 
to practicing HCPs.  
Conclusions 
This study shows that there are significant differences in the nature and extent of training required 
for HCPs to achieve and maintain mastery with different DPI devices. Inhalers that are easier to 
use may facilitate achievement of device mastery and its maintenance over time. Expert tuition 
during initial training may help to optimise HCP knowledge of inhaler use to the extent that 
refreshing HCP skills with minimal instructions (such as written instructions) may be sufficient to 
maintain correct technique over time. Future research should explore the impact of tailored 
education for HCPs on the health care system in terms of clinical and economic outcomes.  
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Figure legends 
 
Figure 1: Overall study design 
At visit 1, participants were randomly assigned to either Spiromax® training followed by 
Turbohaler® training or Turbohaler® training followed by Spiromax® training, in a cross-over 
stage design. Training consisted of 6 consecutive steps until device mastery was achieved, as 
shown in Figure 2. At visits 2 and 3, which commenced 4±1 week and 8±2 weeks after visit 1, 
respectively, participants undertook the same training procedure.  
 
Figure 2: Inhaler technique assessment and training 
At each study visit, participants were assessed on their ability to use the empty study devices 
without training followed by training in a step-wise approach. Training consisted of 6 
consecutive steps: step 1, intuitive use; step 2, use of patient information leaflet; step 3, use of 
instructional video; steps 4-6, expert tuition. Participants progressed from one step to the next 
until device mastery was achieved (defined as absence of assessor-observed serious errors) or 
until all 6 steps were completed. Upon attainment of device mastery, participants proceeded to 
complete the same training and assessment procedure with the second empty device. 
Abbreviations: HCPs = healthcare professionals.  
 
Figure 3: Proportion of participants achieving and maintaining device mastery over the 
study period 
The chart shows the cumulative proportion (%) of participants demonstrating correct inhaler 
technique with the two study devices at each step during the study visits. Total number of 
participants: visit 1, n=516; visit 2, n=498; visit 3, n=460.
  24 
Table 1. Participants achieving device mastery at visit 1  
 
 Irrespective of randomisation order 
 
First randomised device Second randomised device 
 
Training step 
Turbuhaler® 
(n=516) 
 
Spiromax® 
(n=516)  
 
p-valuea 
 
Turbuhaler®  
(n=242) 
 
Spiromax®  
(n=274) 
 
p-valueb 
 
Turbuhaler®  
(n=274) 
 
Spiromax® 
(n=242) 
 
p-valueb 
 
 
1: Intuitive use  
(no training) 
 
20 (4) 
 
113 (22) 
 
<0.001 
 
3 (1) 
 
30 (11) 
 
<0.001 
 
17 (6) 
 
83 (34) 
 
<0.001 
 
2: Patient information leaflet 
 
162 (31) 
 
299 (58) 
 
<0.001 
 
41 (17) 
 
121 (44) 
 
<0.001 
 
121 (44) 
 
178 (74) 
 
<0.001 
 
3: Instructional video 
 
338 (66) 
 
386 (75) 
 
<0.001 
 
130 (54) 
 
182 (66) 
 
0.004 
 
208 (76) 
 
204 (84) 
 
0.024 
 
Data are expressed as cumulative n (%) of participants achieving device mastery by each step. Device mastery (yes/no) was defined as the ability to demonstrate 
inhaler use without assessor-observed errors. Steps 4-6 are not displayed, as no significant difference was detected between the devices at these steps. 
aMcNemar’s test of paired data. bChi-squared test. 
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Table 2. Participants maintaining and achieving device mastery at visit 2 
 
Maintenance of device mastery 
 Irrespective of randomisation order 
 
First randomised device Second randomised device 
 
Training step 
Turbuhaler® 
(n=498) 
 
Spiromax® 
(n=498)  
 
p-valuea 
 
Turbuhaler®  
(n=247) 
 
Spiromax®  
(n=251) 
 
p-valueb 
 
Turbuhaler®  
(n=251) 
 
Spiromax® 
(n=247) 
 
p-valueb 
 
 
1: Intuitive use  
(no training) 
 
202 (41) 
 
317 (64) 
 
<0.001 
 
78 (32) 
 
156 (62) 
 
<0.001 
 
124 (49) 
 
161 (65) 
 
<0.001 
 
Achievement of device mastery 
2: Patient information leaflet 
 
384 (77) 
 
430 (86) 
 
<0.001 
 
174 (70) 
 
215 (86) 
 
<0.001 
 
210 (84) 
 
215 (87) 
 
0.347 
 
3: Instructional video 
 
444 (89) 
 
464 (93) 
 
0.022 
 
211 (85) 
 
234 (93) 
 
0.007 
 
233 (93) 
 
230 (93) 
 
1.00 
 
Data are expressed as cumulative n (%) of participants maintaining/achieving device mastery by each step. Device mastery (yes/no) was defined as the ability to 
demonstrate inhaler use without assessor-observed errors. Steps 4-6 are not displayed, as no significant difference was detected between the devices at these steps. 
aMcNemar’s test of paired data. bChi-squared test. 
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Table 3. Participants maintaining and achieving device mastery at Visit 3 
 
Maintenance of device mastery 
 Irrespective of randomisation order 
 
First randomised device Second randomised device 
 
Training step 
Turbuhaler® 
(n=460) 
 
Spiromax® 
(n=460)  
 
p-valuea 
 
Turbuhaler®  
(n=231) 
 
Spiromax®  
(n=229) 
 
p-valueb 
 
Turbuhaler®  
(n=229) 
 
Spiromax® 
(n=231) 
 
p-valueb 
 
1: Intuitive use  
(no training) 
 
299 (65) 
 
362 (79) 
 
<0.001 
 
143 (62) 
 
168 (73) 
 
0.012 
 
156 (68) 
 
194 (84) 
 
<0.001 
 
Achievement of device mastery 
2: Patient information leaflet 
 
426 (93) 
 
425 (92) 
 
0.893 
 
211 (91) 
 
206 (90) 
 
0.726 
 
215 (94) 
 
219 (95) 
 
0.822 
3: Instructional video 
 
446 (97) 
 
441 (96) 
 
0.353 
 
220 (95) 
 
216 (94) 
 
0.817 
 
226 (99) 
 
225 (97) 
 
0.519 
 
Data are expressed as cumulative n (%) of participants maintaining/achieving device mastery by each step. Device mastery (yes/no) was defined as the ability to 
demonstrate inhaler use without assessor-observed errors. As at steps 2-3, also at steps 4-6 (not shown) no significant difference was detected between the 
devices. aMcNemar’s test of paired data. bChi-squared test.
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Table 4. Most common device errors at each visit 
 
Visit 1 (participants=516) 
Turbuhaler® Spiromax® 
Type of 
error 
Description 
 
n (%)a 
 
Type of 
error 
Description 
 
n (%)a 
 
Dose 
preparation 
Not twisting the base 
as far as possible 
until it clicks and not 
turning it back to the 
original position 
389 (75) Inhalation 
manoeuvre 
Inhalation not as fast 
as possible from the 
start 
337 (65) 
Position Inhaler not held 
upright (mouthpiece 
pointed skywards 
±45°) when a dose is 
prepared 
374 (72) Position Inhaler not held 
upright (±90° is 
correct) when a dose 
is prepared 
225 (44) 
Inhalation 
manoeuvre 
Inhalation not as fast 
as possible from the 
start 
323 (63) 
 
General 
knowledge 
Fails to put in mouth 
and seal lips around 
mouthpiece  
111 (22) 
 
Visit 2 (participants=498) 
Dose 
preparation 
Not twisting the base 
as far as possible 
until it clicks and not 
turning it back to the 
original position 
155 (31) Inhalation 
manoeuvre 
Inhalation not as fast 
as possible from the 
start 
96 (19) 
Position Inhaler not held 
upright (mouthpiece 
pointed skywards 
±45°) when a dose is 
prepared 
132 (27) Position Inhaler not held 
upright (±90° is 
correct) when a dose 
is prepared 
75 (15) 
Inhalation 
manoeuvre 
Inhalation not as fast 
as possible from the 
start 
107 (22) 
 
General 
knowledge 
Puts finger (or face) 
over the air inlet 
during an inhalation 
(at front above the 
mouthpiece) 
30 (6) 
Visit 3 (participants=460) 
Position Inhaler not held 
upright (mouthpiece 
pointed skywards 
±45°) when a dose is 
prepared 
57 (12) Inhalation 
manoeuvre 
Inhalation not as fast 
as possible from the 
start 
50 (11) 
Dose 
preparation 
Not twisting the base 
as far as possible 
until it clicks and not 
turning it back to the 
original position 
35 (8) General 
knowledge 
Puts finger (or face) 
over the air inlet 
during an inhalation 
(at front above the 
mouthpiece) 
24 (5) 
Position Inhaler not held 
upright (mouthpiece 
pointed skywards 
±45°) after the base 
is twisted until 
21(5) Position Inhaler not held 
upright (±90° is 
correct) when a dose 
is prepared 
21 (5) 
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inhalation 
The table shows the distribution of most common types of errors made at each visit, at all steps. aNumber 
and % of participants who made the error. 
 
